RxSpan MD scores 86/100 (grade B, ranked #9) on The Verdict Score. Here are the top-rated GLP-1 providers we'd weigh against it — same six-factor rubric, and no score is adjusted for payment.
A rare oral GLP tablet alongside both injectables, with the full plan table published on-site — though the headline $99 and $179 rates are 12-month prepay floors, not what a month-to-month patient pays.
HealthRX matches RxSpan MD at 86/100; the full HealthRX review has the pricing conditions and the caveats in detail.
A cheap compounded entry with a real brand-Ozempic path and nationwide coverage — but the $179 is a yearly-subscription rate, and Gala publishes no month-to-month price at all, which is what the verdict now docks it hardest for.
Gala Health matches RxSpan MD at 86/100; our Gala Health ruling in full has the pricing conditions and the caveats in detail.
A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — carrying an FDA warning letter from September 2025.
Earns its keep on pricing transparency — every tier is published, dose-flat and includes combo and microdose options — but the verdict holds it back for a compounded-only formulary and a state map it won't show.
Enhance MD scores 85/100 to RxSpan MD's 86; the full Enhance MD review has the pricing conditions and the caveats in detail.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Not medical advice; see our disclosure.